Evidence for the involvement of epigenetics in the progression of renal fibrogenesis

Nephrology Dialysis Transplantation

Volumn 29, Issue SUPPL. 1, 2014, Pages

  Tampe, Björn ^a   Zeisberg, Michael ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

epigenetic; histone modification; hydroxymethylation; kidney fibrosis; methylation

Indexed keywords

EPIGENETIC; HISTONE MODIFICATION; HYDROXYMETHYLATION; KIDNEY FIBROSIS; METHYLATION;

ANIMALS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

AZACITIDINE; BELINOSTAT; DECITABINE; DNA METHYLTRANSFERASE; ENTINOSTAT; GIVINOSTAT; HISTONE H3; HYDRALAZINE; MOCETINOSTAT; PANOBINOSTAT; ROMIDEPSIN; TACEDINALINE; VALPROIC ACID; VORINOSTAT;

CHRONIC KIDNEY DISEASE; CPG ISLAND; DEACETYLATION; DISEASE COURSE; DNA METHYLATION; DRUG EFFICACY; DRUG TARGETING; EPIGENETICS; GENE THERAPY; GENETIC CODE; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; KIDNEY FIBROSIS; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; REVIEW; TRANSCRIPTION INITIATION;

EID: 84893819784     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft361     Document Type: Review

References (91)

1. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-1080
2. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 1999; 99: 451-454
3. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21
4. Marx V. Epigenetics: Reading the second genomic code. Nature 2012; 491: 143-147
5. Dambacher S, Hahn M, Schotta G. Epigenetic regulation of development by histone lysine methylation. Heredity (Edinb) 2010; 105: 24-37
6. Ruthenburg AJ, Li H, Patel DJ et al. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 2007; 8: 983-994
7. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-45
8. Turner BM. Histone acetylation and an epigenetic code. Bioessays 2000; 22: 836-845
9. Tachibana M, Sugimoto K, Fukushima T et al. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. J Biol Chem 2001; 276: 25309-25317
10. Cosgrove MS, Boeke JD, Wolberger C. Regulated nucleosome mobility and the histone code. Nat Struct Mol Biol 2004; 11: 1037-1043
11. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705
12. Lopez-Rodas G, Brosch G, Georgieva EI et al. Histone deacetylase. A key enzyme for the binding of regulatory proteins to chromatin. FEBS Lett 1993; 317: 175-180
13. Khan SN, Danishuddin M, Varshney B et al. Inhibition of N-terminal lysines acetylation and transcription factor assembly by epirubicin induced deranged cell homeostasis. PLoS One 2012; 7: E51850
14. De Ruijter AJ, van Gennip AH, Caron HN et al. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 2003; 370: 737-749
15. Horio Y, Hayashi T, Kuno A et al. Cellular and molecular effects of sirtuins in health and disease. Clin Sci (Lond) 2011; 121: 191-203
16. Marumo T, Hishikawa K, Yoshikawa M et al. Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol 2010; 298: F133-F141
17. Hsing CH, Lin CF, So E et al. alpha2-Adrenoceptor agonist dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5. Am J Physiol Renal Physiol 2012; 303: F1443-F1453
18. Marumo T, Hishikawa K, Yoshikawa M et al. Epigenetic regulation of BMP7 in the regenerative response to ischemia. J Am Soc Nephrol 2008; 19: 1311-1320
19. Yoshikawa M, Hishikawa K, Marumo T et al. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol 2007; 18: 58-65
20. Liu N, He S, Ma L et al. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS One 2013; 8: E54001
21. Van Beneden K, Geers C, Pauwels M et al. Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. Toxicol Appl Pharmacol 2013; 271: 276-284
22. Pang M, Kothapally J, Mao H et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2009; 297: F996-F1005
23. Noh H, Oh EY, Seo JY et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol 2009; 297: F729-F739
24. Liu W, Fan LX, Zhou X et al. HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS One 2012; 7: E49418
25. Gilbert RE, Huang Q, Thai K et al. Histone deacetylase inhibition attenuates diabetes-Associated kidney growth: Potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int 2011; 79: 1312-1321
26. Yang L, Besschetnova TY, Brooks CR et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543. 531p following 143
27. Vastenhouw NL, Schier AF. Bivalent histone modifications in early embryogenesis. Curr Opin Cell Biol 2012; 24: 374-386
28. Sun G, Reddy MA, Yuan H et al. Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol 2010; 21: 2069-2080
29. Lefevre GM, Patel SR, Kim D et al. Altering a histone H3K4 methylation pathway in glomerular podocytes promotes a chronic disease phenotype. PLoS Genet 2010; 6: E1001142
30. Thatcher TH, Gorovsky MA. Phylogenetic analysis of the core histones H2A, H2B, H3, and H4. Nucleic Acids Res 1994; 22: 174-179
31. Jackson JD, Gorovsky MA. Histone H2A.Z has a conserved function that is distinct from that of the major H2A sequence variants. Nucleic Acids Res 2000; 28: 3811-3816
32. Allis CD, Glover CV, Bowen JK et al. Histone variants specific to the transcriptionally active, amitotically dividing macronucleus of the unicellular eucaryote, tetrahymena thermophila. Cell 1980; 20: 609-617
33. Marques M, Laflamme L, Gervais AL et al. Reconciling the positive and negative roles of histone H2A.Z in gene transcription. Epigenetics 2010; 5: 267-272
34. Guillemette B, Bataille AR, Gevry N et al. Variant histone H2A.Z is globally localized to the promoters of inactive yeast genes and regulates nucleosome positioning. PLoS Biol 2005; 3: E384
35. Zlatanova J, Thakar A. H2a.Z: View from the top. Structure 2008; 16: 166-179
36. Zager RA, Johnson AC. Renal ischemia-reperfusion injury upregulates histone-modifying enzyme systems and alters histone expression at proinflammatory/ profibrotic genes. Am J Physiol Renal Physiol 2009; 296: F1032-F1041
37. Rogakou EP, Boon C, Redon C et al. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 1999; 146: 905-916
38. Goldberg M, Stucki M, Falck J et al. MDC1 is required for the intra-Sphase DNA damage checkpoint. Nature 2003; 421: 952-956
39. Cook PJ, Ju BG, Telese F et al. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 2009; 458: 591-596
40. Lu C, Zhu F, Cho YY et al. Cell apoptosis: Requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol Cell 2006; 23: 121-132
41. Ali BH, Al-Husseni I, Beegam S et al. Effect of gum arabic on oxidative stress and inflammation in adenine-induced chronic renal failure in rats. PLoS One 2013; 8: E55242
42. Estecio MR, Issa JP. Dissecting DNA hypermethylation in cancer. FEBS Lett 2011; 585: 2078-2086
43. Wade PA. Methyl CpG binding proteins: Coupling chromatin architecture to gene regulation. Oncogene 2001; 20: 3166-3173
44. Mohn F, Weber M, Rebhan M et al. Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell 2008; 30: 755-766
45. Parry L, Clarke AR. The roles of the methyl-CpG binding proteins in cancer. Genes Cancer 2011; 2: 618-630
46. Klose RJ, Bird AP. Genomic DNA methylation: The mark and its mediators. Trends Biochem Sci 2006; 31: 89-97
47. Berger J, Bird A. Role of MBD2 in gene regulation and tumorigenesis. Biochem Soc Trans 2005; 33: 1537-1540
48. Dhasarathy A, Wade PA. The MBD protein family-reading an epigenetic mark? Mutat Res 2008; 647: 39-43
49. Nan X, Ng HH, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386-389
50. Bostick M, Kim JK, Esteve PO et al. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007; 317: 1760-1764
51. Sharif J, Muto M, Takebayashi S et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 2007; 450: 908-912
52. Achour M, Jacq X, Ronde P et al. The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene 2008; 27: 2187-2197
53. Lei H, Oh SP, Okano M et al. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development 1996; 122: 3195-3205
54. Shenker N, Flanagan JM. Intragenic DNA methylation: Implications of this epigenetic mechanism for cancer research. Br J Cancer 2012; 106: 248-253
55. Hellman A, Chess A. Gene body-specific methylation on the active X chromosome. Science 2007; 315: 1141-1143
56. Ball MP, Li JB, Gao Y et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009; 27: 361-368
57. Maunakea AK, Nagarajan RP, Bilenky M et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010; 466: 253-257
58. Shukla S, Kavak E, Gregory M et al. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 2011; 479: 74-79
59. Bechtel W, McGoohan S, Zeisberg EM et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010; 16: 544-550
60. Tao H, Huang C, Yang JJ et al. MeCP2 controls the expression of RASAL1 in the hepatic fibrosis in rats. Toxicology 2011; 290: 327-333
61. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 1998; 19: 219-220
62. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69: 915-926
63. Vertino PM, Yen RW, Gao J et al. De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)- methyltransferase. Mol Cell Biol 1996; 16: 4555-4565
64. Pradhan S, Bacolla A, Wells RD et al. Recombinant human DNA (cytosine- 5) methyltransferase. I. expression, purification, and comparison of de novo and maintenance methylation. J Biol Chem 1999; 274: 33002-33010
65. Kho MR, Baker DJ, Laayoun A et al. Stalling of human DNA (cytosine-5) methyltransferase at single-strand conformers from a site of dynamic mutation. J Mol Biol 1998; 275: 67-79
66. Chuang LS, Ian HI, Koh TW et al. Human DNA-(cytosine-5) methyltransferase- PCNA complex as a target for p21WAF1. Science 1997; 277: 1996-2000
67. Hashimoto H, Liu Y, Upadhyay AK et al. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res 2012; 40: 4841-4849
68. Robertson KD, Uzvolgyi E, Liang G et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999; 27: 2291-2298
69. Bestor TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000; 9: 2395-2402
70. Poulsen HE. Oxidative DNA modifications. Exp Toxicol Pathol 2005; 57 (Suppl 1): 161-169
71. Dhe-Paganon S, Syeda F, Park L. DNA methyl transferase 1: Regulatory mechanisms and implications in health and disease. Int J Biochem Mol Biol 2011; 2: 58-66
72. Wu SC, Zhang Y. Active DNA demethylation: Many roads lead to Rome. Nat Rev Mol Cell Biol 2010; 11: 607-620
73. Tahiliani M, Koh KP, Shen Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-935
74. Ito S, D'Alessio AC, Taranova OV et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129-1133
75. Shen L, Kantarjian H, Guo Y et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28: 605-613
76. Ficz G, Branco MR, Seisenberger S et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011; 473: 398-402
77. Dawlaty MM, Ganz K, Powell BE et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 2011; 9: 166-175
78. Bocker MT, Tuorto F, Raddatz G et al. Hydroxylation of 5-methylcytosine by TET2 maintains the active state of the mammalian HOXA cluster. Nat Commun 2012; 3: 818
79. Gu TP, Guo F, Yang H et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011; 477: 606-610
80. Xu Y, Xu C, Kato A et al. Tet3 CXXC domain and dioxygenase activity cooperatively regulate key genes for Xenopus eye and neural development. Cell 2012; 151: 1200-1213
81. Pradhan M, Esteve PO, Chin HG et al. CXXC domain of human DNMT1 is essential for enzymatic activity. Biochemistry 2008; 47: 10000-10009
82. Allen MD, Grummitt CG, Hilcenko C et al. Solution structure of the nonmethyl- CpG-binding CXXC domain of the leukaemia-Associated MLL histone methyltransferase. EMBO J 2006; 25: 4503-4512
83. Langemeijer SM, Aslanyan MG, Jansen JH. TET proteins in malignant hematopoiesis. Cell Cycle 2009; 8: 4044-4048
84. Bieliauskas AV, Pflum MK. Isoform-selective histone deacetylase inhibitors. Chem Soc Rev 2008; 37: 1402-1413
85. Yoshikawa M, Hishikawa K, Idei M et al. Trichostatin a prevents TGFbeta1- induced apoptosis by inhibiting ERK activation in human renal tubular epithelial cells. Eur J Pharmacol 2010; 642: 28-36
86. Qi W, Mu J, Luo ZF et al. Attenuation of diabetic nephropathy in diabetes rats induced by streptozotocin by regulating the endoplasmic reticulum stress inflammatory response. Metabolism 2011; 60: 594-603
87. Foulks JM, Parnell KM, Nix RN et al. Epigenetic drug discovery: Targeting DNA methyltransferases. J Biomol Screen 2012; 17: 2-17
88. Sun CY, Chang SC, Wu MS. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 2012; 81: 640-650
89. Billings FTt, Chen SW, Kim M et al. alpha2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol 2008; 295: F741-F748
90. Si Y, Bao H, Han L et al. Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation. J Transl Med 2013; 11: 141
91. Imai N, Hishikawa K, Marumo T et al. Inhibition of histone deacetylase activates side population cells in kidney and partially reverses chronic renal injury. Stem Cells 2007; 25: 2469-2475